Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 1/2020

01-02-2020 | Molsidomine | Research Article

Potential drug–drug interactions associated with clinical and laboratory findings at hospital admission

Authors: Milena Kovačević, Sandra Vezmar Kovačević, Slavica Radovanović, Predrag Stevanović, Branislava Miljković

Published in: International Journal of Clinical Pharmacy | Issue 1/2020

Login to get access

Abstract

Background Drug–drug interactions represent one of the causes of adverse therapy outcomes through deteriorated efficacy or safety. However, the true extent of harm related to drug–drug interactions is not well established due to a lack of recognition and understanding. Objective The aim of this study was to investigate the association of potential drug–drug interactions with patients variables recorded at admission. Setting A cross-sectional correlation study was performed on the Cardiology ward of the University Clinical Hospital Center in Belgrade, Serbia. Method Data were retrospectively obtained from medical records and LexiInteract was used as the screening tool for potential drug–drug interactions. Main outcome measure Clinical and laboratory parameters recorded at the patients admission. Results A total of 351 patient records entered the analysis, with the mean age of 70 ± 10 years. The prevalence of potentially relevant drug–drug interactions was 61% (N = 213). After controlling for patient characteristics, nine potential drug–drug interactions were significantly associated with laboratory values outside the range and five potential drug–drug interactions with inadequate clinical parameter values. Potential drug–drug interactions were associated with abnormalities in blood count, metabolic parameters, electrolyte imbalance and renal function parameters. Association with inadequate control of systolic, diastolic blood pressure, as well as heart rhythm was also shown. Conclusion Drug–drug interactions were associated with patients clinical and laboratory findings. Our findings may assist in the identification of patients with increased likelihood of suboptimal therapy outcomes. Generating evidence through post-marketing drug–drug interactions research would lead to improvement in clinical decision-support systems, increased effectiveness and utilization in everyday clinical practice.
Literature
1.
go back to reference Bansilal S, Castellano JM, Fuster V. Global burden of CVD: focus on secondary prevention of cardiovascular disease. Int J Cardiol. 2015;201(Suppl 1):S1–7.PubMed Bansilal S, Castellano JM, Fuster V. Global burden of CVD: focus on secondary prevention of cardiovascular disease. Int J Cardiol. 2015;201(Suppl 1):S1–7.PubMed
2.
go back to reference Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34:2940–8.PubMed Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34:2940–8.PubMed
3.
go back to reference Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125:882–7.PubMed Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125:882–7.PubMed
4.
go back to reference Patel TK, Patel PB. Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis. Eur J Clin Pharmacol. 2018;74:819–32.PubMed Patel TK, Patel PB. Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis. Eur J Clin Pharmacol. 2018;74:819–32.PubMed
5.
go back to reference Lin CW, Wen YW, Chen LK, Hsiao FY. Potentially high-risk medication categories and unplanned hospitalizations: a case-time-control study. Sci Rep. 2017;7:41035.PubMedPubMedCentral Lin CW, Wen YW, Chen LK, Hsiao FY. Potentially high-risk medication categories and unplanned hospitalizations: a case-time-control study. Sci Rep. 2017;7:41035.PubMedPubMedCentral
6.
go back to reference Patel NS, Patel TK, Patel PB, Naik VN, Tripathi CB. Hospitalizations due to preventable adverse reactions-a systematic review. Eur J Clin Pharmacol. 2017;73:385–98.PubMed Patel NS, Patel TK, Patel PB, Naik VN, Tripathi CB. Hospitalizations due to preventable adverse reactions-a systematic review. Eur J Clin Pharmacol. 2017;73:385–98.PubMed
7.
go back to reference Oscanoa TJ, Lizaraso F, Carvajal A. Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis. Eur J Clin Pharmacol. 2017;73:759–70.PubMed Oscanoa TJ, Lizaraso F, Carvajal A. Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis. Eur J Clin Pharmacol. 2017;73:759–70.PubMed
8.
go back to reference Aagaard L, Strandell J, Melskens L, Petersen PS, Holme HE. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase. Drug Saf. 2012;35:1171–82.PubMed Aagaard L, Strandell J, Melskens L, Petersen PS, Holme HE. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase. Drug Saf. 2012;35:1171–82.PubMed
9.
go back to reference Hines LE, Murphy JE. Potentially harmful drug–drug interactions in the elderly: a review. Am J Geriatr Pharmacother. 2011;9:364–77.PubMed Hines LE, Murphy JE. Potentially harmful drug–drug interactions in the elderly: a review. Am J Geriatr Pharmacother. 2011;9:364–77.PubMed
10.
go back to reference Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug–drug interactions. Expert Opin Drug Saf. 2012;11:83–94.PubMed Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug–drug interactions. Expert Opin Drug Saf. 2012;11:83–94.PubMed
11.
go back to reference Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329:15–9.PubMedPubMedCentral Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329:15–9.PubMedPubMedCentral
12.
go back to reference Dechanont S, Maphanta S, Butthum B, Kongkaew C. Hospital admissions/visits associated with drug–drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2014;23:489–97.PubMed Dechanont S, Maphanta S, Butthum B, Kongkaew C. Hospital admissions/visits associated with drug–drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2014;23:489–97.PubMed
13.
go back to reference Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS ONE. 2009;4:e4439.PubMedPubMedCentral Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS ONE. 2009;4:e4439.PubMedPubMedCentral
14.
go back to reference Kovacevic M, VezmarKovacevic S, Radovanovic S, Stevanovic P, Miljkovic B. Adverse drug reactions caused by drug–drug interactions in cardiovascular disease patients: introduction of a simple prediction tool using electronic screening database items. Curr Med Res Opin. 2019;35:1873–83.PubMed Kovacevic M, VezmarKovacevic S, Radovanovic S, Stevanovic P, Miljkovic B. Adverse drug reactions caused by drug–drug interactions in cardiovascular disease patients: introduction of a simple prediction tool using electronic screening database items. Curr Med Res Opin. 2019;35:1873–83.PubMed
15.
go back to reference Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH. Hospitalisations and emergency department visits due to drug–drug interactions: a literature review. Pharmacoepidemiol Drug Saf. 2007;16:641–51.PubMed Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH. Hospitalisations and emergency department visits due to drug–drug interactions: a literature review. Pharmacoepidemiol Drug Saf. 2007;16:641–51.PubMed
16.
go back to reference KrahenbuhlMelcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krahenbuhl S. Drug-related problems in hospitals: a review of the recent literature. Drug Saf. 2007;30:379–407. KrahenbuhlMelcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krahenbuhl S. Drug-related problems in hospitals: a review of the recent literature. Drug Saf. 2007;30:379–407.
17.
go back to reference Alvim MM, Silva LA, Leite IC, Silverio MS. Adverse events caused by potential drug–drug interactions in an intensive care unit of a teaching hospital. Rev Bras Ter Intensiva. 2015;27:353–9.PubMedPubMedCentral Alvim MM, Silva LA, Leite IC, Silverio MS. Adverse events caused by potential drug–drug interactions in an intensive care unit of a teaching hospital. Rev Bras Ter Intensiva. 2015;27:353–9.PubMedPubMedCentral
18.
go back to reference Zheng WY, Richardson LC, Li L, Day RO, Westbrook JI, Baysari MT. Drug–drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2018;74:15–27.PubMed Zheng WY, Richardson LC, Li L, Day RO, Westbrook JI, Baysari MT. Drug–drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2018;74:15–27.PubMed
19.
go back to reference Cecchi E. Drug–drug interaction knowledge to save the patient from iatrogenic disease and to improve the diagnostic process. Intern Emerg Med. 2019;14:345–7.PubMed Cecchi E. Drug–drug interaction knowledge to save the patient from iatrogenic disease and to improve the diagnostic process. Intern Emerg Med. 2019;14:345–7.PubMed
20.
go back to reference Alshammari TM. Drug safety: the concept, inception and its importance in patients' health. Saudi Pharm J. 2016;24:405–12.PubMed Alshammari TM. Drug safety: the concept, inception and its importance in patients' health. Saudi Pharm J. 2016;24:405–12.PubMed
21.
go back to reference Mugosa S, Bukumiric Z, Kovacevic A, Boskovic A, Protic D, Todorovic Z. Adverse drug reactions in hospitalized cardiac patients: characteristics and risk factors. Vojnosanit Pregl. 2015;72:975–81.PubMed Mugosa S, Bukumiric Z, Kovacevic A, Boskovic A, Protic D, Todorovic Z. Adverse drug reactions in hospitalized cardiac patients: characteristics and risk factors. Vojnosanit Pregl. 2015;72:975–81.PubMed
22.
go back to reference Klopotowska JE, Wierenga PC, Smorenburg SM, Stuijt CC, Arisz L, Kuks PF, et al. Recognition of adverse drug events in older hospitalized medical patients. Eur J Clin Pharmacol. 2013;69:75–85.PubMed Klopotowska JE, Wierenga PC, Smorenburg SM, Stuijt CC, Arisz L, Kuks PF, et al. Recognition of adverse drug events in older hospitalized medical patients. Eur J Clin Pharmacol. 2013;69:75–85.PubMed
23.
go back to reference Kovacevic M, Kovacevic SV, Miljkovic B, Radovanovic S, Stevanovic P. The prevalence and preventability of potentially relevant drug–drug interactions in patients admitted for cardiovascular diseases: a cross-sectional study. Int J Clin Pract. 2017;71:e13005. Kovacevic M, Kovacevic SV, Miljkovic B, Radovanovic S, Stevanovic P. The prevalence and preventability of potentially relevant drug–drug interactions in patients admitted for cardiovascular diseases: a cross-sectional study. Int J Clin Pract. 2017;71:e13005.
24.
go back to reference Roblek T, Trobec K, Mrhar A, Lainscak M. Potential drug–drug interactions in hospitalized patients with chronic heart failure and chronic obstructive pulmonary disease. Arch Med Sci. 2014;10:920–32.PubMedPubMedCentral Roblek T, Trobec K, Mrhar A, Lainscak M. Potential drug–drug interactions in hospitalized patients with chronic heart failure and chronic obstructive pulmonary disease. Arch Med Sci. 2014;10:920–32.PubMedPubMedCentral
25.
go back to reference Urbina O, Ferrandez O, Luque S, Grau S, Mojal S, Pellicer R, et al. Patient risk factors for developing a drug-related problem in a cardiology ward. Ther Clin Risk Manag. 2015;11:9–15.PubMed Urbina O, Ferrandez O, Luque S, Grau S, Mojal S, Pellicer R, et al. Patient risk factors for developing a drug-related problem in a cardiology ward. Ther Clin Risk Manag. 2015;11:9–15.PubMed
26.
go back to reference Marusic S, Bacic-Vrca V, ObreliNeto PR, Franic M, Erdeljic V, Gojo-Tomic N. Actual drug–drug interactions in elderly patients discharged from internal medicine clinic: a prospective observational study. Eur J Clin Pharmacol. 2013;69:1717–24.PubMed Marusic S, Bacic-Vrca V, ObreliNeto PR, Franic M, Erdeljic V, Gojo-Tomic N. Actual drug–drug interactions in elderly patients discharged from internal medicine clinic: a prospective observational study. Eur J Clin Pharmacol. 2013;69:1717–24.PubMed
27.
go back to reference Kongkaew C, Hann M, Mandal J, Williams SD, Metcalfe D, Noyce PR, et al. Risk factors for hospital admissions associated with adverse drug events. Pharmacotherapy. 2013;33:827–37.PubMed Kongkaew C, Hann M, Mandal J, Williams SD, Metcalfe D, Noyce PR, et al. Risk factors for hospital admissions associated with adverse drug events. Pharmacotherapy. 2013;33:827–37.PubMed
28.
go back to reference Davies EA, O'Mahony MS. Adverse drug reactions in special populations—the elderly. Br J Clin Pharmacol. 2015;80:796–807.PubMedPubMedCentral Davies EA, O'Mahony MS. Adverse drug reactions in special populations—the elderly. Br J Clin Pharmacol. 2015;80:796–807.PubMedPubMedCentral
29.
go back to reference Marino A, Capogrosso-Sansone A, Tuccori M, Bini G, Calsolaro V, Mantarro S, et al. Expected and actual adverse drug–drug interactions in elderly patients accessing the emergency department: data from the ANCESTRAL-ED study. Expert Opin Drug Saf. 2016;15:45–50.PubMed Marino A, Capogrosso-Sansone A, Tuccori M, Bini G, Calsolaro V, Mantarro S, et al. Expected and actual adverse drug–drug interactions in elderly patients accessing the emergency department: data from the ANCESTRAL-ED study. Expert Opin Drug Saf. 2016;15:45–50.PubMed
30.
go back to reference Wilbur K, Hazi H, ElBedawi A. Drug-related hospital visits and admissions associated with laboratory or physiologic abnormalities—a systematic-review. PLoS ONE. 2013;8:e66803.PubMedPubMedCentral Wilbur K, Hazi H, ElBedawi A. Drug-related hospital visits and admissions associated with laboratory or physiologic abnormalities—a systematic-review. PLoS ONE. 2013;8:e66803.PubMedPubMedCentral
31.
go back to reference Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125:2309–21.PubMed Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125:2309–21.PubMed
32.
go back to reference Brook RD, Anderson JA, Calverley PM, Celli BR, Crim C, Denvir MA, et al. Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. Heart. 2017;103:1536–42.PubMed Brook RD, Anderson JA, Calverley PM, Celli BR, Crim C, Denvir MA, et al. Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. Heart. 2017;103:1536–42.PubMed
34.
go back to reference Navarro JF, Mora C, Muros M, Garcia J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol. 2005;16:2119–266.PubMed Navarro JF, Mora C, Muros M, Garcia J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol. 2005;16:2119–266.PubMed
35.
go back to reference Lin SL, Chen YM, Chiang WC, Wu KD, Tsai TJ. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. Am J Kidney Dis. 2008;52:464–74.PubMed Lin SL, Chen YM, Chiang WC, Wu KD, Tsai TJ. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. Am J Kidney Dis. 2008;52:464–74.PubMed
36.
go back to reference Goicoechea M, de Vinuesa SG, Quiroga B, Verdalles U, Barraca D, Yuste C, et al. Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial. J Nephrol. 2012;25:969–75.PubMed Goicoechea M, de Vinuesa SG, Quiroga B, Verdalles U, Barraca D, Yuste C, et al. Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial. J Nephrol. 2012;25:969–75.PubMed
37.
go back to reference Rodriguez-Moran M, Gonzalez-Gonzalez G, Bermudez-Barba MV, de la Garza CEM, TamezPerez HE, Martinez-Martinez FJ, et al. Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: a double-blind, placebo-controlled randomized trial. Clin Nephrol. 2006;66:3–10.PubMed Rodriguez-Moran M, Gonzalez-Gonzalez G, Bermudez-Barba MV, de la Garza CEM, TamezPerez HE, Martinez-Martinez FJ, et al. Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: a double-blind, placebo-controlled randomized trial. Clin Nephrol. 2006;66:3–10.PubMed
38.
go back to reference Maiti R, Agrawal NK, Dash D, Pandey BL. Effect of Pentoxifylline on inflammatory burden, oxidative stress and platelet aggregability in hypertensive type 2 diabetes mellitus patients. Vascul Pharmacol. 2007;47:118–24.PubMed Maiti R, Agrawal NK, Dash D, Pandey BL. Effect of Pentoxifylline on inflammatory burden, oxidative stress and platelet aggregability in hypertensive type 2 diabetes mellitus patients. Vascul Pharmacol. 2007;47:118–24.PubMed
39.
go back to reference Navarro-Gonzalez JF, Muros M, Mora-Fernandez C, Herrera H, Meneses B, Garcia J. Pentoxifylline for renoprotection in diabetic nephropathy: the PREDIAN study. Rationale and basal results. J Diabetes Complications. 2011;25:314–9.PubMed Navarro-Gonzalez JF, Muros M, Mora-Fernandez C, Herrera H, Meneses B, Garcia J. Pentoxifylline for renoprotection in diabetic nephropathy: the PREDIAN study. Rationale and basal results. J Diabetes Complications. 2011;25:314–9.PubMed
40.
go back to reference DiPetrillo K, Gesek FA. Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. Am J Nephrol. 2004;24:352–9.PubMed DiPetrillo K, Gesek FA. Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. Am J Nephrol. 2004;24:352–9.PubMed
41.
go back to reference Chang AR, Sang Y, Leddy J, Yahya T, Kirchner HL, Inker LA, et al. Antihypertensive medications and the prevalence of hyperkalemia in a large health system. Hypertension. 2016;67:1181–8.PubMed Chang AR, Sang Y, Leddy J, Yahya T, Kirchner HL, Inker LA, et al. Antihypertensive medications and the prevalence of hyperkalemia in a large health system. Hypertension. 2016;67:1181–8.PubMed
42.
go back to reference Geerts AF, De Koning FH, De Smet PA, Van Solinge WW, Egberts TC. Laboratory tests in the clinical risk management of potential drug–drug interactions: a cross-sectional study using drug-dispensing data from 100 Dutch community pharmacies. Drug Saf. 2009;32:1189–97.PubMed Geerts AF, De Koning FH, De Smet PA, Van Solinge WW, Egberts TC. Laboratory tests in the clinical risk management of potential drug–drug interactions: a cross-sectional study using drug-dispensing data from 100 Dutch community pharmacies. Drug Saf. 2009;32:1189–97.PubMed
43.
go back to reference Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365:2002–12.PubMed Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365:2002–12.PubMed
44.
go back to reference Bykov K, Gagne JJ. Generating evidence of clinical outcomes of drug–drug interactions. Drug Saf. 2017;40:101–3.PubMed Bykov K, Gagne JJ. Generating evidence of clinical outcomes of drug–drug interactions. Drug Saf. 2017;40:101–3.PubMed
Metadata
Title
Potential drug–drug interactions associated with clinical and laboratory findings at hospital admission
Authors
Milena Kovačević
Sandra Vezmar Kovačević
Slavica Radovanović
Predrag Stevanović
Branislava Miljković
Publication date
01-02-2020
Publisher
Springer International Publishing
Keyword
Molsidomine
Published in
International Journal of Clinical Pharmacy / Issue 1/2020
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-019-00951-y

Other articles of this Issue 1/2020

International Journal of Clinical Pharmacy 1/2020 Go to the issue